The Company is subject to the provisions of the City Code on Takeovers and Mergers.
Verici Dx has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.
Number of AIM securities in issue: 141,747,816 shares are issued, called up and fully paid. The Company holds no shares in treasury.
This figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
|Significant shareholders||No. of ordinary shares||% held|
Icahn School of Medicine at Mount Sinai
|Renalytix AI plc||9,831,681||6.9%|
|Unicorn Asset Management Limited||5,739,660||4.0%|
|Amati Global Investors||4,964,533||3.5%|
|Hargreaves Lansdown Asset Management||4,579,204||3.2%|
*Christopher Mills is partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher’s shareholding is made up of 16,500,000 ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC, 5,500,000 ordinary shares are held by Oryx International Growth Fund Limited and 1,722,501 ordinary shares are held by Harwood Capital LLP.
On the date of Admission
|Director||Number||Ordinary Shares %|
|Julian Baines MBE||1,351,713||1%|
|Sir Ian Carruthers||100,000||0.1%|
Percentage of securities not in public hands: As at 9 August 2021 the percentage of AIM securities not in the public hands was 41.7%. The securities not in public hands include all substantial shareholders and the directors and senior management who are classed as persons discharging managerial responsibilities.
There are no restrictions on the transfer of the Company’s ordinary shares except for shareholders who received distribution in specie from Renalytix AI plc.
Last updated: 9 August 2021